234 related articles for article (PubMed ID: 38036507)
1. RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis.
Li Z; Caron de Fromentel C; Kim W; Wang WH; Sun J; Yan B; Utturkar S; Lanman NA; Elzey BD; Yeo Y; Zhang H; Kazemian M; Levrero M; Andrisani O
Cell Death Dis; 2023 Nov; 14(11):786. PubMed ID: 38036507
[TBL] [Abstract][Full Text] [Related]
2. Restoration of RNA helicase DDX5 suppresses hepatitis B virus (HBV) biosynthesis and Wnt signaling in HBV-related hepatocellular carcinoma.
Mani SKK; Yan B; Cui Z; Sun J; Utturkar S; Foca A; Fares N; Durantel D; Lanman N; Merle P; Kazemian M; Andrisani O
Theranostics; 2020; 10(24):10957-10972. PubMed ID: 33042264
[No Abstract] [Full Text] [Related]
3. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
4. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
[TBL] [Abstract][Full Text] [Related]
5. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
6. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
7. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
8. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
Lo RC; Leung CO; Chan KK; Ho DW; Wong CM; Lee TK; Ng IO
Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma.
Seo SH; Cho KJ; Park HJ; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Cheon JH; Yook JI; Kim MD; Joo DJ; Kim SU
Cell Commun Signal; 2023 Nov; 21(1):339. PubMed ID: 38012711
[TBL] [Abstract][Full Text] [Related]
10. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
Li J; Li Y; Wang D; Liao R; Wu Z
J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
[TBL] [Abstract][Full Text] [Related]
11. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
[TBL] [Abstract][Full Text] [Related]
12. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
13. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
14. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
[TBL] [Abstract][Full Text] [Related]
15. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
[TBL] [Abstract][Full Text] [Related]
16. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
17. Spindle and kinetochore-associated protein 2 facilitates the proliferation and invasion of hepatocellular carcinoma via the regulation of Wnt/β-catenin signaling.
Jiang J; Xu B; Zheng Y; Guo X; Chen F
Exp Cell Res; 2020 Oct; 395(1):112181. PubMed ID: 32682011
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling.
Wei Y; Shen N; Wang Z; Yang G; Yi B; Yang N; Qiu Y; Lu J
Mol Cell Biochem; 2013 Sep; 381(1-2):139-44. PubMed ID: 23756716
[TBL] [Abstract][Full Text] [Related]
19. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
[TBL] [Abstract][Full Text] [Related]
20. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
Lin YT; Chao CC
Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
